Brookline Capital Management Forecasts Strong Price Appreciation for Lisata Therapeutics (NASDAQ:LSTA) Stock

Lisata Therapeutics (NASDAQ:LSTA) had its price target lifted by investment analysts at Brookline Capital Management from $20.00 to $32.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Lisata Therapeutics Stock Performance

Shares of LSTA stock opened at $2.57 on Tuesday. The stock has a fifty day moving average price of $2.58 and a 200 day moving average price of $2.58. The stock has a market cap of $22.15 million, a PE ratio of -1.12 and a beta of 1.03. Lisata Therapeutics has a 1 year low of $1.87 and a 1 year high of $4.20.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). As a group, equities research analysts predict that Lisata Therapeutics will post -2.66 earnings per share for the current year.

Institutional Trading of Lisata Therapeutics

An institutional investor recently bought a new position in Lisata Therapeutics stock. Citadel Advisors LLC purchased a new stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 23,273 shares of the company’s stock, valued at approximately $69,000. Citadel Advisors LLC owned about 0.28% of Lisata Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.